Drug intelligence / Profile preview

pexidartinib + sirolimus

Development stage: Unknown
Lead developer: Plexxikon
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of pexidartinib, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, and sirolimus, an mTOR inhibitor. This combination targets tumor-associated macrophage (TAM) polarization, particularly depleting M2-type macrophages which are associated with tumor progression. Preclinical studies showed that the combination resulted in increased apoptosis and suppressed signaling pathways (AKT, KIT, and S6 phosphorylation) that neither drug could achieve independently.

Brand names: Turalio + sirolimus

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)CSF1R (Macrophage colony-stimulating factor receptor)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on pexidartinib + sirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pexidartinib + sirolimus.

Explore the full profile